Method for generating Retinal Pigment Epithelium (RPE) cells from Induced Pluripotent Stem Cells (IPSCs)

• US 10,480,031 B2
• Filed: 05/02/2018
• Issued: 11/19/2019
• Est. Priority Date: 02/01/2013
• Status: Active Grant

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Original Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
• Inventors: Bharti, Kapil, Davis, Janine
• Primary Examiner(s): Singh, Anoop K
• Assistant Examiner(s): Sgagias, Magdalene K
• Application Number:
  US15/969,686
• Publication Number:
  US 20180291448A1
• Time in Patent Office: 566 Days
• Field of Search: None
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2501/999 Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2506/45 from artificially induced pluripotent stem cells
• CPC Class Codes: C12N 5/0621 Eye cells, e.g. cornea, iris pigmented cells photoreceptors C12N5/062
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA
• CPC Class Codes: G01N 33/5058 Neurological cells
• CPC Class Codes: G01N 33/56966 Animal cells

Abstract

High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.

Claims

1. A method for producing human retinal pigment epithelial (RPE) cells, comprising:

(a) culturing human induced pluripotent stem cells (hiPSCs) in a human embryonic stem cell culture medium comprising human basic fibroblast growth factor (bFGF) and not containing ingredients obtained from non-human animals to produce small embryoid bodies of 200-500 cells;

(b) culturing the small embryoid bodies from step (a) in a first medium comprising retinal induction medium (RIM) and rock inhibitor (RI), wherein the RIM comprises Wnt inhibitor CK1-7, a Nodal pathway inhibitor, Noggin, and 1 to 3% v/v knockout serum replacement, wherein the Nodal pathway inhibitor is SB-431542 or SB-505124, to form embryoid bodies that have increased efficiency of RPE differentiation;

(c) culturing the embryoid bodies that have increased efficiency of RPE differentiation from step (b) on a matrigel coated tissue culture substrate-in a second medium comprising a retinal differentiation medium that does not comprise basic fibroblast growth factor (bFGF) and comprises Dickkopf-related protein 1 (DKK1), CK1-7, a bFGF inhibitor, and Noggin, wherein the bFGF inhibitor is PD0325901, PD98059, PD161570, or PD166285, to form differentiating RPE cells that express PAX6 and MITF;

(d) culturing the differentiating RPE cells from step (C) in a third medium comprising retinal media comprising Activin A and Wnt3a to produce cells that have increased expression of MITF and PAX6 and increased RPE differentiation efficiency; and

(e) culturing the cells that have increased expression of MITF and PAX6 and increased RPE differentiation efficiency from step (d) in a fourth medium comprising a RPE cell medium comprising a non-canonical Wnt 5a inducer, DKK1, SU5402, and cyclopamine to produce human RPE cells that express TYR, TYRP1, MYRIP, Cadherin 1 or Cadherin 3 and TRPMI 1 or TRPMI 3, thereby producing human RPE cells.

2. The method of claim 1, wherein the first medium comprises 3.5 to 9 mM of CKI-7.

3. The method of claim 1, wherein the Nodal pathway inhibitor is SB-431542.

4. The method of claim 3, wherein the first medium comprises 3.5 to 9 mM of SB-431542.

5. The method of claim 1, wherein the retinal induction medium does not comprise serum.

6. The method of claim 1, wherein the inhibitor of bFGF is PD032590.

7. The method of claim 6, wherein the second medium comprises 0.5 to 2 mM of PD0325901.

8. The method of claim 1, wherein the second medium comprises 3.5 to 9 mM of CK1-7 and 3.5 to 9 mM of SB-431542.

9. The method of claim 1, wherein the first medium comprises 50 ng/ml of Dickkopf-related protein 1 (DKK1).

10. The method of claim 1, wherein the third medium comprises 100 to 200 ng/ml of Activin A.

11. The method of claim 1, wherein the third medium comprises 75 to 150 ng/ml of Wnt3a.

12. The method of claim 1, wherein the second medium comprises 75 to 150 ng/ml of DKK1.

13. The method of claim 1, wherein the fourth medium comprises 75 to 150 ng/ml of WNT5a, 75 to 150 ng/ml of DKK1, 5 μ

M Cycolopamine and 10 μ

M of SU5402.

14. The method of claim 1, wherein step (a) comprises culturing the cells in the presence of 1.5% v/v knock out serum replacement.

15. The method of claim 1, wherein the tissue culture substrate is a transwell plate.

16. The method of claim 1, further comprising expressing OCT4, SOX2, LIN28 and Nanog in a human fetal RPE cell to produce the human induced pluripotent stem cells.

17. The method of claim 1, wherein the human induced pluripotent stem cells comprise a nucleic acid encoding a marker operably linked to a RPE cell specific promoter.

18. The method of claim 17, wherein the retinal specific promoter is a tyrosinase promoter.

19. The method of claim 1, wherein the embryoid bodies are cultured in the first medium for 48 hours.

20. The method of claim 1 wherein the embryoid bodies are cultured in the second medium for 18 to 24 days.

21. The method of claim 20, wherein the embryoid bodies are cultured in the second medium for three weeks.

22. The method of claim 1, wherein the differentiating RPE cells are cultured in the third medium for 18 to 24 days.

23. The method of claim 22, wherein the differentiating RPE cells are cultured in the third medium for three weeks.

24. The method of claim 1, wherein the cells are cultured in the fourth medium for 12 to 16 days.

25. The method of claim 24, wherein the cells are cultured in the fourth medium for two weeks.

26. The method of claim 1, further comprising maintaining the RPE cells in the fourth medium and 5% v/v fetal serum.

27. The method of claim 26, comprising maintaining the RPE cells in the fourth medium and 5% v/v fetal serum for six to eight weeks.